IGCClosing triangle and gap indicator. Possibly another drop to .40s or maybe even .30s This has been a hopeful bottom for many markets.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1224 USD
−13.00 M USD
1.34 M USD
55.48 M
About IGC Pharma, Inc.
Sector
Industry
CEO
Ram Mukunda
Website
Headquarters
Potomac
Founded
2005
FIGI
BBG000NSSLY8
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
IgcI'm really for new adventure with this pump and dumb stock.
Buying zone 0.45 - 0.75
Never invest money that you can't afford to lose
Good luck
IGC India Globalization Capital bullish newsAfter the last pump and dump of IGC caused by Cohort 2 of IGC`s Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
now India Globalization Capital comes with another bullish news on the subject: the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer’s tr
IGC updateCongratz if you followed my last prediction:
I updated the chart, see above.
I am still confident will we step even higher, but first we have to accept the next pullback.
IGC PullbackIGC started yesterday pretty good, I expect a pullback followed by an bullrun until earnings.
Risk/Reward looks good - Stop Loss at 1.44$.
Lotto Ticket Play, Highly ManipulatedJust something I remembered from a few years back. Love that tradingview play button, so figured I'd post the look just to see what will happen. Noticed it was moving.
Back in 2018, for awhile it was the darling of speculatives in the weed stock sector, rising from sub $1.00 to $15.00. That was
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of IGC is 0.2900 USD — it has increased by 0.68% in the past 24 hours. Watch IGC Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange IGC Pharma, Inc. stocks are traded under the ticker IGC.
IGC stock has risen by 7.28% compared to the previous week, the month change is a −15.01% fall, over the last year IGC Pharma, Inc. has showed a −33.18% decrease.
We've gathered analysts' opinions on IGC Pharma, Inc. future price: according to them, IGC price has a max estimate of 4.25 USD and a min estimate of 3.50 USD. Watch IGC chart and read a more detailed IGC Pharma, Inc. stock forecast: see what analysts think of IGC Pharma, Inc. and suggest that you do with its stocks.
IGC stock is 4.84% volatile and has beta coefficient of 0.38. Track IGC Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is IGC Pharma, Inc. there?
Today IGC Pharma, Inc. has the market capitalization of 22.42 M, it has increased by 1.47% over the last week.
Yes, you can track IGC Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
IGC Pharma, Inc. is going to release the next earnings report on Jun 18, 2025. Keep track of upcoming events with our Earnings Calendar.
IGC earnings for the last quarter are −0.02 USD per share, whereas the estimation was −0.03 USD resulting in a 33.33% surprise. The estimated earnings for the next quarter are −0.02 USD per share. See more details about IGC Pharma, Inc. earnings.
IGC Pharma, Inc. revenue for the last quarter amounts to 257.00 K USD, despite the estimated figure of 204.00 K USD. In the next quarter, revenue is expected to reach 305.00 K USD.
IGC net income for the last quarter is −1.83 M USD, while the quarter before that showed −1.72 M USD of net income which accounts for −6.52% change. Track more IGC Pharma, Inc. financial stats to get the full picture.
No, IGC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 67 employees. See our rating of the largest employees — is IGC Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IGC Pharma, Inc. EBITDA is −7.55 M USD, and current EBITDA margin is −681.12%. See more stats in IGC Pharma, Inc. financial statements.
Like other stocks, IGC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IGC Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IGC Pharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IGC Pharma, Inc. stock shows the sell signal. See more of IGC Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.